August 30, 2024 by Hayley Mignacca, University of Massachusetts Medical School Lyz-IFNγR2−/− mice are rescued from fatty liver progression to MASH. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-49633-yResearch from the lab of Jason Kim, Ph.D., professor of molecular medicine and medicine, identified a novel pathway in the progression of metabolic liver disease that could be targeted...
by King’s College London Credit: CC0 Public Domain Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease. A new paper, published today in The Lancet by King’s College London and the Catholic University of Rome, is the first to compare three active treatments of non-alcoholic steatohepatitis (NASH) and to...
